Lexaria Bioscience Expands Patent Portfolio with Five New Grants, Including Diabetes Treatment Patents

Lexaria Bioscience Corp. has expanded its intellectual property portfolio with five newly granted patents, including two specifically for diabetes treatment using GLP-1 drugs. The company, which trades on Nasdaq under the symbol LEXX, announced the patents were awarded in Japan and Australia across three different patent families covering hypertension, epilepsy, and diabetes treatments.

The most significant development involves two new Australian patents in the company’s newest patent family covering diabetes treatments. These patents, numbered 2025205229 and 2024394427, were issued on February 12, 2026 and will remain in effect until December 3, 2044. They specifically cover compositions and methods for treating diabetes using Lexaria’s proprietary DehydraTECH technology in conjunction with already-approved GLP-1 drugs. This comes at a time when the GLP-1 industry is experiencing intense international competition, making these patents particularly valuable. The company’s recent Phase 1b Human Study (GLP-1-H24-4) conducted in Australia provided supporting evidence for the capabilities of this technology combination.

In Japan, Lexaria received two new patents in its hypertension treatment family, numbered 7823051 and 7823052, both issued on February 20, 2026 with protection extending to April 25, 2043. The company already held three U.S. patents and one European patent in this same family prior to these Japanese grants. For epilepsy treatment, Lexaria secured one new Australian patent (2024205127) issued on February 12, 2026 with a term ending February 20, 2044, adding to its existing portfolio of six U.S. patents, one European Union patent, and four previous Australian patents in this therapeutic area.

CEO Richard Christopher emphasized the importance of these developments, particularly the diabetes-related patents. ‘Given the international race within the GLP-1 industry, our new patents related to diabetes treatments utilizing our proprietary technology in conjunction with already-approved GLP-1 drugs is a notable achievement,’ Christopher stated. The company’s DehydraTECH technology is designed to improve how drugs enter the bloodstream through oral delivery, potentially increasing bio-absorption while reducing side effects.

Lexaria’s expanding patent portfolio now includes 65 granted patents worldwide with additional applications pending. The company maintains a licensed in-house research laboratory and continues dedicated research and development programs aimed at both advancing commercial relationships and establishing valuable intellectual property in multiple jurisdictions. These latest patent awards strengthen the company’s position in competitive pharmaceutical markets while providing additional protection for its drug delivery platform technology across three significant therapeutic areas.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Lexaria Bioscience Expands Patent Portfolio with Five New Grants, Including Diabetes Treatment Patents.

The post Lexaria Bioscience Expands Patent Portfolio with Five New Grants, Including Diabetes Treatment Patents appeared first on citybuzz.